| Dr Daniel Christian Hobbs, MD | |
|
1880 Amherst Street, Suite 100 And Suite 200, Winchester, VA 22601 | |
| (540) 662-0306 | |
| (855) 264-2066 |
| Full Name | Dr Daniel Christian Hobbs |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 1880 Amherst Street, Winchester, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922418185 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 29927 (West Virginia) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0101269934 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Winchester Medical Center | Winchester, VA | Hospital |
| War Memorial Hospital Inc | Berkeley springs, WV | Hospital |
| Page Memorial Hospital, Inc | Luray, VA | Hospital |
| Hampshire Memorial Hospital | Romney, WV | Hospital |
| Shenandoah Memorial Hospital | Woodstock, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Page Memorial Hospital Inc | 8426951203 | 43 |
| Shenandoah Memorial Hospital, Inc. | 2466360375 | 41 |
| Valley Physician Enterprise Inc | 9931268091 | 205 |
| Warren Memorial Hospital, Inc. | 2365330347 | 71 |
| Winchester Medical Center | 0244134021 | 124 |
| East Mountain Health Physicians Inc | 9133405327 | 75 |
| War Memorial Hospital, Inc. | 1355479460 | 14 |
News Archive
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.
Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.
A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain - and can also experience their relief following treatment.
MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
› Verified 1 days ago
| Entity Name | Winchester Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679711261 PECOS PAC ID: 0244134021 Enrollment ID: O20031124000061 |
News Archive
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.
Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.
A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain - and can also experience their relief following treatment.
MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
› Verified 1 days ago
| Entity Name | Shenandoah Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952417735 PECOS PAC ID: 2466360375 Enrollment ID: O20040115001156 |
News Archive
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.
Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.
A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain - and can also experience their relief following treatment.
MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
› Verified 1 days ago
| Entity Name | Page Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326040684 PECOS PAC ID: 8426951203 Enrollment ID: O20040129000420 |
News Archive
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.
Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.
A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain - and can also experience their relief following treatment.
MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
› Verified 1 days ago
| Entity Name | Warren Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164442281 PECOS PAC ID: 2365330347 Enrollment ID: O20040310000516 |
News Archive
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.
Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.
A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain - and can also experience their relief following treatment.
MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
› Verified 1 days ago
| Entity Name | Valley Physician Enterprise Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538316203 PECOS PAC ID: 9931268091 Enrollment ID: O20081104000278 |
News Archive
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.
Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.
A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain - and can also experience their relief following treatment.
MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Christian Hobbs, MD 220 Campus Blvd Ste 100, Winchester, VA 22601-2888 Ph: (540) 536-5100 | Dr Daniel Christian Hobbs, MD 1880 Amherst Street, Suite 100 And Suite 200, Winchester, VA 22601 Ph: (540) 662-0306 |
News Archive
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.
Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.
A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain - and can also experience their relief following treatment.
MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
› Verified 1 days ago
Dr. Raveen Chawla, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1880 Amherst Street, Suite 100 And Suite 200, Winchester, VA 22601 Phone: 540-662-0306 Fax: 855-264-2066 | |
Dr. Neal S Gaither, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1880 Amherst Street, Suite 100 And Suite 200, Winchester, VA 22601 Phone: 540-662-0306 Fax: 855-264-2066 | |
Dr. Lee Resta, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 400 Campus Blvd Ste 100, Winchester, VA 22601 Phone: 540-662-1108 | |
Kristine Gade Reed, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 400 Campus Blvd., Suite 100, Winchester, VA 22601 Phone: 540-662-1108 Fax: 540-450-2244 | |
Dr. David Jack Lecronier, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 190 Campus Blvd Ste 201, Winchester, VA 22601 Phone: 540-536-5980 Fax: 540-536-5979 | |
T. Glen Bouder, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8874 Fax: 540-536-7847 | |
Dr. Manish J Lakhani, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1880 Amherst Street, Suite 100 And Suite 200, Winchester, VA 22601 Phone: 540-662-0306 Fax: 855-264-2066 |